NBDF/LinkedIn
Jul 28, 2025, 15:18
Investigational Therapies for VWD and Glanzmann Thrombasthenia Unveiled at ISTH 2025: 2 Promising Paths Forward
National Bleeding Disorders Foundation (NBDF) shared a post on LinkedIn:
”Big strides in bleeding disorders care! Hemab Therapeutics shares new data on two potential preventive therapies for Glanzmann thrombasthenia and VWD.”
Read the full update here.

Stay updated on the latest news in hematology with Hemostasis Today.
-
Nov 21, 2026, 08:21Jenni Majumdar: What Changing Blood Transfusion Guidelines Mean for Patients and Surgical Teams
-
Nov 21, 2026, 08:17Doaa El Demerdash: The Bridge Meeting Fosters International Dialogue on Hemophilia Care
-
Nov 21, 2026, 08:16Emily Branchard: Uncoupling Anticancer and Antiplatelet Effects of Dipyridamole Analogs
-
Nov 21, 2026, 08:10Rory R Koenen: Xin Xin Earns PhD for Research on Extracellular Vesicles and Vascular Inflammation
-
Nov 21, 2026, 08:06Andrew Hill: How Do You Build Loyalty when Financial Incentives Are off the Table?
-
Nov 21, 2026, 08:00Kevin Dean: How Leptin Receptor Positive Stromal Cells Regulate Platelet Production
-
Nov 21, 2026, 07:59William Aird: The Blood Project Makes Its First Appearance at ASH 2026
-
Nov 21, 2026, 07:52Michael Holmes: Why Matched Platelet Donations Matter for Refractory Patients
-
Nov 21, 2026, 07:18Raising Awareness of Inherited Bleeding Disorders in Women and Girls – World Federation of Hemophilia